Alexandre Lebeaut has more than 25 years of a valuable experience and leadership both in innovation, research and development, from preclinical to post-marketing stage and with major achievements in particular in immunology, oncology, immuno-inflammation and infectious diseases. He has held various global positions, notably in the United States at Bluebird Bio, Sanofi, Novartis and Schering Plough Research Institute. Most recently, Alexandre Lebeaut served as Executive Vice-President R&D and Chief Scientific Officer at Ipsen in the US. He currently heads “I-ACT for Children” (Institute for Advanced Clinical Trials), an American non-profit organization based in Maryland which is dedicated to pediatric drug development.
Alexandre is a French and US citizen and is a Doctor of Medicine (University of Paris Diderot Paris VII) and a pediatrician (University of Paris Descartes).